CS
NRC icon

Credit Suisse’s NRC Health Common Stock NRC Stock Holding History

Credit Suisse’s Portfolio NRC Stock Details NRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.3M Buy
32,885
+1,193
+4% +$47.2K ﹤0.01% 2113
2023
Q4 		$1.25M Buy
31,692
+3,566
+13% +$149K ﹤0.01% 2190
2023
Q3 		$1.25M Sell
28,126
-666
-2% -$29.1K ﹤0.01% 2149
2023
Q2 		$1.25M Buy
28,792
+1,132
+4% +$49.8K ﹤0.01% 2232
2023
Q1 		$1.2M Buy
27,660
+1,578
+6% +$69.7K ﹤0.01% 2217
2022
Q4 		$973K Buy
26,082
+4,000
+18% +$155K ﹤0.01% 2362
2022
Q3 		$879K Buy
22,082
+2,236
+11% +$82.8K ﹤0.01% 2423
2022
Q2 		$760K Buy
19,846
+4,287
+28% +$155K ﹤0.01% 2569
2022
Q1 		$617K Buy
15,559
+707
+5% +$27.7K ﹤0.01% 2848
2021
Q4 		$617K Sell
14,852
-543
-4% -$23.6K ﹤0.01% 3666
2021
Q3 		$649K Buy
15,395
+551
+4% +$27.7K ﹤0.01% 3640
2021
Q2 		$682K Buy
14,844
+1,721
+13% +$81.9K ﹤0.01% 3644
2021
Q1 		$614K Sell
13,123
-5,538
-30% -$269K ﹤0.01% 3640
2020
Q4 		$797K Buy
18,661
+5,730
+44% +$294K ﹤0.01% 3498
2020
Q3 		$636K Sell
12,931
-1,082
-8% -$59.9K ﹤0.01% 3246
2020
Q2 		$816K Buy
14,013
+6,065
+76% +$320K ﹤0.01% 3019
2020
Q1 		$361K Buy
7,948
+681
+9% +$40.9K ﹤0.01% 3301
2019
Q4 		$479K Sell
7,267
-9,384
-56% -$574K ﹤0.01% 3596
2019
Q3 		$961K Buy
16,651
+9,817
+144% +$608K ﹤0.01% 3042
2019
Q2 		$393K Sell
6,834
-981
-13% -$45.4K ﹤0.01% 3536
2019
Q1 		$302K Buy
7,815
+666
+9% +$26.1K ﹤0.01% 3596
2018
Q4 		$273K Buy
7,149
+1,925
+37% +$74K ﹤0.01% 3553
2018
Q3 		$202K Sell
5,224
-3,078
-37% -$117K ﹤0.01% 3652
2018
Q2 		$310K Sell
8,302
-421
-5% -$14.7K ﹤0.01% 3619
2018
Q1 		$255K Buy
8,723
+37
+0.4% +$1.24K ﹤0.01% 3632
2017
Q4 		$323K Buy
8,686
+293
+3% +$10.4K ﹤0.01% 3605
2017
Q3 		$316K Buy
+8,393
New +$264K ﹤0.01% 3715

Other funds holding NRC

Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's NRC Position: Q1 2024 in Review

Credit Suisse increased its NRC Health Common Stock (NRC) stake by 3.8% in Q1 2024, buying an estimated $47.2K and bringing the position to 32,885 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2113.

Credit Suisse first reported a position in NRC in Q3 2017 and has held it in 27 quarters since. 142 funds tracked by Wall St. Rank hold NRC as of Q1 2024.

  • Credit Suisse held 32,885 shares of NRC Health Common Stock worth $1.3M as of Q1 2024.
  • Credit Suisse bought 1,193 NRC Health Common Stock shares in Q1 2024, an estimated $47.2K.
  • NRC Health Common Stock made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2113 holding.
  • Credit Suisse first reported a position in NRC Health Common Stock in Q3 2017 and has held it in 27 quarters since.
  • 142 funds tracked by Wall St. Rank held NRC Health Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.